MX2017004131A - Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo. - Google Patents
Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo.Info
- Publication number
- MX2017004131A MX2017004131A MX2017004131A MX2017004131A MX2017004131A MX 2017004131 A MX2017004131 A MX 2017004131A MX 2017004131 A MX2017004131 A MX 2017004131A MX 2017004131 A MX2017004131 A MX 2017004131A MX 2017004131 A MX2017004131 A MX 2017004131A
- Authority
- MX
- Mexico
- Prior art keywords
- chronic
- blood
- component
- mammal
- autologous composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
Abstract
Se describen métodos de producción de una composición autóloga útil para el tratamiento de tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos y/o condiciones degenerativas crónicas de las articulaciones y trastornos inflamatorios de la piel en un mamífero; el método comprende preparar un componente anti-inflamatorio/anti-catabólico de la composición autóloga que comprende IL-1ra y TIMPs; se prepara un componente anti-inflamatorio/anti-catabólico que comprende: colectar sangre del mamífero; suministrar la sangre a un tubo; incubar la sangre a una temperatura de aproximadamente 37°C a aproximadamente 39°C por aproximadamente 24 horas, de preferencia en presencia de citrato de sodio; centrifugar la sangre para separar la sangre en un componente de sobrenadante y una fracción celular; y colectar el componente de sobrenadante; el método comprende además el paso de preparar un componente regenerativo de la composición autóloga que comprende: colectar sangre del mamífero; suministrar la sangre a un tubo en presencia de ácido cítrico a aproximadamente 4%; centrifugar la sangre para separar un componente de plasma rico en plaquetas de la sangre entera; colectar el componente de plasma rico en plaquetas; y mezclar el componente de sobrenadante con el componente de plasma rico en plaquetas para proveer la composición autóloga; se provee también un método de tratamiento de tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos y/o condiciones degenerativas crónicas de las articulaciones y trastornos inflamatorios de la piel en un sujeto con la composición autóloga, y una composición autóloga para el tratamiento de tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos y/o condiciones degenerativas crónicas de las articulaciones y trastornos inflamatorios de la piel en un mamífero, y el uso de la composición autóloga para el tratamiento de tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos y/o condiciones degenerativas crónicas de las articulaciones y trastornos inflamatorios de la piel en un mamífero.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2866480A CA2866480A1 (en) | 2014-09-30 | 2014-09-30 | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
| CA2891445A CA2891445A1 (en) | 2014-09-30 | 2015-05-14 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
| CA2900537A CA2900537A1 (en) | 2014-09-30 | 2015-08-13 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
| PCT/CA2015/000521 WO2016049746A1 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004131A true MX2017004131A (es) | 2017-06-19 |
Family
ID=55590205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004131A MX2017004131A (es) | 2014-09-30 | 2015-09-30 | Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10532072B2 (es) |
| EP (1) | EP3200817B1 (es) |
| JP (1) | JP6646660B2 (es) |
| KR (1) | KR102455394B1 (es) |
| CN (1) | CN107073083B (es) |
| AU (1) | AU2015327723B2 (es) |
| BR (1) | BR112017006410A2 (es) |
| CA (4) | CA2866480A1 (es) |
| CL (1) | CL2017000670A1 (es) |
| ES (1) | ES2912773T3 (es) |
| GB (1) | GB2546224B (es) |
| IL (1) | IL251082B (es) |
| LT (1) | LT3200817T (es) |
| MX (1) | MX2017004131A (es) |
| RU (1) | RU2708242C2 (es) |
| WO (1) | WO2016049746A1 (es) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532072B2 (en) | 2014-09-30 | 2020-01-14 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
| US12023352B2 (en) | 2014-09-30 | 2024-07-02 | Antnor Limited | Anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2950659A1 (en) * | 2016-12-06 | 2018-06-06 | Antnor Limited | Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma |
| EP3613424A1 (en) * | 2018-08-23 | 2020-02-26 | Orthogen AG | Novel methods for the production of pharmaceutical agents |
| WO2020243807A1 (en) * | 2019-06-05 | 2020-12-10 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
| RU2747589C1 (ru) * | 2019-12-09 | 2021-05-11 | Руслан Яверович Атлуханов | Способ лечения повреждения мениска коленного сустава |
| CA3076046A1 (en) * | 2020-03-17 | 2021-09-17 | Antnor Limited | Method for producing enhanced anti-inflammatory/anti-catabolic agents from autologous physiological fluid with shortened incubation time |
| CA3106197A1 (en) * | 2021-01-20 | 2022-07-20 | Antnor Limited | Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines |
| JP7025070B1 (ja) * | 2021-05-14 | 2022-02-24 | セルソース株式会社 | 血液由来成長因子含有組成物及びその調製方法 |
| JP7175055B1 (ja) * | 2021-05-14 | 2022-11-18 | セルソース株式会社 | 血液由来成長因子含有組成物及びその調製方法 |
| CN114146096B (zh) * | 2021-11-25 | 2024-04-02 | 成都清科生物科技有限公司 | 一种富含细胞因子的条件血清的制备方法及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09509681A (ja) | 1994-12-16 | 1997-09-30 | バクスター、インターナショナル、インコーポレイテッド | 供血者血液特性の制御 |
| DE19903876B4 (de) * | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten |
| US20060177515A1 (en) | 2005-02-09 | 2006-08-10 | Reinhold Schmieding | Method of producing autogenous or allogenic blood serum and related logistics |
| GB0700940D0 (en) | 2007-01-18 | 2007-02-28 | Univ Newcastle | Reverse shoulder prosthesis |
| EP2620139B1 (en) | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
| US8460227B2 (en) * | 2008-11-17 | 2013-06-11 | Arthrex, Inc. | Cytokine concentration system |
| AU2010292486B2 (en) | 2009-08-27 | 2014-08-07 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| MX2013002488A (es) | 2010-09-03 | 2013-06-03 | Biomet Biologics Llc | Métodos y composiciones para suministrar un antagonista del receptor interleucina-1. |
| KR101313755B1 (ko) | 2010-12-09 | 2013-10-01 | 이선민 | 상피조직 또는 피하조직 재생용 자가혈장의 제조방법 및 이를 함유하는 조성물 |
| WO2013114359A1 (en) | 2012-01-31 | 2013-08-08 | Estar Technologies Ltd | System and method for producing interleukin receptor antagonist (ira) |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| CA2866480A1 (en) | 2014-09-30 | 2016-03-30 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
-
2014
- 2014-09-30 CA CA2866480A patent/CA2866480A1/en not_active Abandoned
-
2015
- 2015-05-14 CA CA2891445A patent/CA2891445A1/en not_active Abandoned
- 2015-08-13 CA CA2900537A patent/CA2900537A1/en not_active Abandoned
- 2015-09-30 CN CN201580053264.6A patent/CN107073083B/zh active Active
- 2015-09-30 US US15/515,996 patent/US10532072B2/en active Active
- 2015-09-30 CA CA2962289A patent/CA2962289C/en active Active
- 2015-09-30 BR BR112017006410A patent/BR112017006410A2/pt active Search and Examination
- 2015-09-30 EP EP15847588.9A patent/EP3200817B1/en active Active
- 2015-09-30 WO PCT/CA2015/000521 patent/WO2016049746A1/en active Application Filing
- 2015-09-30 MX MX2017004131A patent/MX2017004131A/es unknown
- 2015-09-30 ES ES15847588T patent/ES2912773T3/es active Active
- 2015-09-30 RU RU2017114523A patent/RU2708242C2/ru active
- 2015-09-30 GB GB1706803.2A patent/GB2546224B/en active Active
- 2015-09-30 JP JP2017518238A patent/JP6646660B2/ja active Active
- 2015-09-30 KR KR1020177011345A patent/KR102455394B1/ko active IP Right Grant
- 2015-09-30 AU AU2015327723A patent/AU2015327723B2/en active Active
- 2015-09-30 LT LTEPPCT/CA2015/000521T patent/LT3200817T/lt unknown
-
2017
- 2017-03-09 IL IL251082A patent/IL251082B/en active IP Right Grant
- 2017-03-20 CL CL2017000670A patent/CL2017000670A1/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532072B2 (en) | 2014-09-30 | 2020-01-14 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
| US12023352B2 (en) | 2014-09-30 | 2024-07-02 | Antnor Limited | Anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
Also Published As
| Publication number | Publication date |
|---|---|
| LT3200817T (lt) | 2022-08-10 |
| IL251082A0 (en) | 2017-04-30 |
| IL251082B (en) | 2020-03-31 |
| CA2962289C (en) | 2021-01-19 |
| CA2866480A1 (en) | 2016-03-30 |
| EP3200817B1 (en) | 2022-03-02 |
| JP6646660B2 (ja) | 2020-02-14 |
| RU2017114523A (ru) | 2018-11-07 |
| US20170296583A1 (en) | 2017-10-19 |
| CL2017000670A1 (es) | 2017-11-10 |
| RU2708242C2 (ru) | 2019-12-05 |
| JP2017533896A (ja) | 2017-11-16 |
| ES2912773T3 (es) | 2022-05-27 |
| CA2900537A1 (en) | 2016-03-30 |
| GB201706803D0 (en) | 2017-06-14 |
| KR102455394B1 (ko) | 2022-10-17 |
| GB2546224B (en) | 2020-04-22 |
| EP3200817A1 (en) | 2017-08-09 |
| WO2016049746A1 (en) | 2016-04-07 |
| RU2017114523A3 (es) | 2019-05-06 |
| CA2962289A1 (en) | 2016-04-07 |
| GB2546224A (en) | 2017-07-12 |
| CA2891445A1 (en) | 2016-03-30 |
| US20200163991A1 (en) | 2020-05-28 |
| CN107073083A (zh) | 2017-08-18 |
| CN107073083B (zh) | 2021-07-06 |
| BR112017006410A2 (pt) | 2017-12-19 |
| AU2015327723A1 (en) | 2017-04-13 |
| AU2015327723B2 (en) | 2020-10-22 |
| US10532072B2 (en) | 2020-01-14 |
| EP3200817A4 (en) | 2018-06-20 |
| KR20170063836A (ko) | 2017-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2546224A (en) | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| PH12019500440A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| EA201891374A1 (ru) | Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение | |
| WO2014152029A3 (en) | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors | |
| WO2015112793A3 (en) | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof | |
| SV2011003828A (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
| SG10201809947UA (en) | Use of prg4 as an anti-inflammatory agent | |
| BR112015021888A2 (pt) | inibidores de dna-ik | |
| IN2012DN02645A (es) | ||
| JP2017533896A5 (es) | ||
| MY176631A (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
| EP2467167A4 (en) | APTAMERS DIRECTED AGAINST A TISSUE FACTOR PATH INHIBITOR AND THEIR USE AS THERAPEUTIC AGENTS AGAINST BLEEDING DISORDERS | |
| WO2014183033A3 (en) | G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal | |
| NZ616048A (en) | Administration of iloprost as aerosol bolus | |
| MX2017001433A (es) | Sistema de bioprocesamiento a microescala y metodo para fabricacion de proteina a partir de sangre humana. | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| MX2022011489A (es) | Metodo para producir agentes antiinflamatorios/anticatabolicos mejorados a partir de fluido fisiologico autologo. | |
| MX2016013680A (es) | Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. | |
| RU2015104076A (ru) | Композиция с факторами роста для применения в интраназальном лечении нейродегенеративного заболевания или других заболеваний центральной нервной системы и способ ее получения | |
| Tani et al. | A Case of Extraction of an Implant after Type I Thyroplasty | |
| PH12020551493A1 (en) | Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors | |
| RU2017131907A (ru) | Способ биотехнологического восстановления кожного покрова аллогенными стволовыми клетками человека | |
| UA106238U (uk) | Спосіб оцінки ефективності лікування лацидипіном хворих з легеневою гіпертензією на фоні ішемічної хвороби серця |